Article
This article was written by Dr. Milton Packer, who wonders why physicians are struggling to get their priorities straight.
All News
Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.
Article
While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.
Article
The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.
Article
The results of the KEEPSaKE-1 study in psoriatic arthritis (PsA) has been published and shows that risankizumab (RIZ), an IL-23 inhibitor, showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.
Article
Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.
Dr. John Cush
Tweet
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients
 https://t.co/MrywKZKcIV https://t.co/QgajVPdesg
Dr. John Cush
Tweet
Study 126 rheumatic disease (RMD) patients showed that post-vaccination flares of RMD are rare. Despite being on DMARDs, biologics, immunosuppressives, the rate of RMD reactivation was 0.007 person/mo. 5 mild articular flares in 3 women https://t.co/OWXWTedw3Q
Dr. John Cush
Tweet
Can PPI accelerate knee OA? UK cohort compared need for TKR in adults over 50yrs on PPI or H2 blockers. Those on omeprazole and pantoprazole had 21%-3& more TKR than H2B (but not elevated with lansoprazole, rabeprazole (HR=0.97) https://t.co/5TqFV3TpjG
Dr. John Cush
Tweet
FDA has approved an NGF inhibitor for arthritis in cats...yes CATS! Presumeably for OA, Solensia (frunevetmab) is a cat-specific MAb that binds nerve growth factor (NGF). In humans several NGF MAbs have failed (tanezumab in 2021) https://t.co/WcvXP8Bv21
Dr. John Cush
Tweet
KEEPSaKe-1 Trial in PsA - IL-23 Inhibition is Effective
The KEEPSaKE-1 study in PsA has been published and shows that RIZ showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD.
https://t.co/thYavd4dAR https://t.co/HnVtsrUgVB
Dr. John Cush
Tweet
JAMA cohort study of 5.9 million VA pts and with & without gout ( 556 521)-gout pts had higher rates of lower extremity amputation (HR 1.59), than those without gout. This was assoc w/ poor uric acid control (>7), but not urate lowering therapy. https://t.co/KiM3IBCCp4
Dr. John Cush
Tweet
Global Burden of Disease Study shows that globally, from 1990 to 2019, the age-standardized incidence rate (ASIR) of hip osteoarthritis increased from 17.02 per 100,000 persons to 18.70 per 100,000 persons https://t.co/OJOnkAw1Dy
Dr. John Cush
Tweet
JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/6dRd6gnkjc
Dr. John Cush
Tweet
NEJM: A 14-year-old boy was admitted to this hospital because of fatigue, fever, joint pain, abdominal cramping, and diarrhea. Start w/ Sore, throat, then polyarthritis (knees, Shoul), fever 39.4C. Very high WBC, CRP & lipase. Whats the Dx?
Dr. John Cush
Tweet
Biomarker study of 21 systemic juvenile idiopathic arthritis (sJIA) shows you can differentiate between active & inactive disease. From 69 biomarkers, these were predictive: IL-6, MMP1, S100A12 (p < 0.0001), HMGB1; but IL-18 elevated in both groups! https://t.co/m2yXTITzwY
Dr. John Cush
Tweet
Single center comparison of pts with MAS vs malignancy assoc. HLH (mHLH) - overall MAS had less hepatomegaly (0 v 25%), double platelet #s (50 v 29Kµ/L), but lower sIL-2R (6814 vs. 27,972.0) and less mortality (22 v 44%, p=0.18). https://t.co/NGIaPTU0yT
Dr. John Cush
Tweet
Register for RheumNow Live, March 19-20, 2022.
You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office.
You can also receive CME credit!
https://t.co/fYyV75vAWm https://t.co/zOpCbBrzHJ
Dr. John Cush
Tweet
New podcast available for download.
2021 Rheumatology Year in Review
https://t.co/0Lpo0IUBHp https://t.co/ysdwmQjeaS
Dr. John Cush
Tweet
There were significantly fewer FDA advisory committee meetings in 2021 (n=10), down dramatically from 35 in 2012, 29 in 2018. Nonetheless the FDA did approve 50 new drugs (NDA) in 2021. https://t.co/rSzHkIMEfg
